WO2004069234A1 - Pharmaceutical compositions and process of production thereof - Google Patents
Pharmaceutical compositions and process of production thereof Download PDFInfo
- Publication number
- WO2004069234A1 WO2004069234A1 PCT/IN2003/000312 IN0300312W WO2004069234A1 WO 2004069234 A1 WO2004069234 A1 WO 2004069234A1 IN 0300312 W IN0300312 W IN 0300312W WO 2004069234 A1 WO2004069234 A1 WO 2004069234A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- metoprolol
- composition according
- cellulose
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the invention relates to the field of medicine and pharmacology. More specifically, the invention relates to an extended release oral dosage pharmaceutical composition comprising metoprolol or a pharmaceutically acceptable succinate salt thereof provided with an extended release polymer base retardant coating, and to a process for its production.
- Metoprolol succinate is a beta-selective (cardioselective) adrenoreceptor blocking agent, for oral administration, available as extended release tablets to treat the heart condition angina.
- the drug reduces the oxygen demand to the heart, slowing the heart rate, reducing cardiac output when at rest and on exercise and reduces systolic blood pressure among other things.
- metoprolol formulations already known, which usually comprise controlled release pellets, wherein each pellet acts as a separate drug delivery unit. But in order to obtain a desirable release of a drug, a considerable amount of experimentation needs to be performed. So, in accordance with the present investigation, an extended release pharmaceutical formulation has been devised which releases the drug for up to 24 hours in a suitably controlled manner.
- U.S. Patent 4792452 to Howard et al. describes a controlled release pharmaceutical formulation which releases the drug at a controlled rate regardless of the pH of the environment. Its formulation includes up to about 45% by weight of a pH dependent polymer, which is a salt of alginic acid in addition to a pH independent hydrocarbon gelling agent, such as hydroxypropylmethyl cellulose.
- EP 0293347 to Henry A.C. and Christina E.E. describes metoprolol succinate as a new therapeutically active compound, and pharmaceutical preparations comprising it.
- This invention discusses a new oral, therapeutically active compound, which is soluble in the pH range 1 to 8, which therefore can be released in the gastrointestinal tract below the upper part of the small intestine.
- the sustained release excipient is prepared by dry blending the requisite amounts of xanthan gum, dextrose and calcium sulfate.
- U.S. Patent 4871549 to Yoshio U. et al describes a time controlled explosion system comprising metoprolol, a swelling agent such as a low substituted hydroxypropylcellulose, sodium starch glycolate or carboxymethylcellulose sodium, coated with a water-insoluble coating material so that drug release is caused by the explosion of the membrane after a definite time period.
- a swelling agent such as a low substituted hydroxypropylcellulose, sodium starch glycolate or carboxymethylcellulose sodium
- U.S. Patent 4927640 to Dahlinder L-ED et al also describes controlled release beads having a glass or silicon dioxide core. Metoprolol succinate was sprayed onto the cores of silicon dioxide, glass and sodium chloride from a solution of ethanol 95% and methylene chloride. Then the coated beads were filled into hard gelatin capsules.
- U.S. Patent 5081154 to Henry A.C. and Christina E.E. which is a continuation of EP 0293346 also relates to metoprolol succinate wherein an oral pharmaceutical composition comprising a core containing a therapeutically active compound is disclosed.
- the core has been coated with a layer comprising an anionic polymer and a water insoluble polymer selected from the group of quaternary ammonium substituted acrylic polymers.
- the investigators suggest that in order to achieve a steady blood plasma level of the therapeutically active compound, a split dose unit of the therapeutically active compound provided with a coating according to the present invention can be administered together with some particles/granules which are not coated.
- U.S. Patent 5399358 to Stanoforth George N and Baichwal Anand R is directed to sustained release formulations which provide a 24 hour release of metoprolol using a combination of xanthan gum with locust bean gum as the preferred gum combination.
- EP Application 110542 by McCall Troy W and Baichwal Anand R describes once-a- day oral dosage form of metoprolol to be released over a period of 24 hours in the gastrointestinal tract.
- the sustained release matrix comprises heterosaccharide derivatives of xanthan gum.
- a number of patents in the prior art deal with sustained or controlled release formulations of metoprolol. These include water insoluble glass, silicon dioxide or plastic resin beads, which are sprayed with metoprolol salt and then coated with controlled release polymeric membrane.
- Another sustained release excipient commonly used is a heteropolysaccharide e.g., xanthan gum or a gum combination of xanthan and locust bean gum for delaying the drug release.
- xanthan gum or a gum combination of xanthan and locust bean gum for delaying the drug release.
- a pharmaceutical composition comprising a matrix material having metoprolol, or a pharmaceutically acceptable salt thereof, dispersed therein, the dispersion of the metoprolol or pharmaceutically acceptable salt thereof within the matrix material being effective to delay the release profile on administration of the pharmaceutical composition, the tablet being provided with a substantially water-insoluble polymeric coating effective further to delay the release profile on administration of the pharmaceutical composition.
- pharmaceutically acceptable salt is a succinate.
- the matrix material may be capable of forming a swelling gel when in contact with water and may comprise a cellulosic polymer and a carbomer.
- the cellulosic polymer is preferably hydroxypropyl methyl cellulose.
- the polymeric coating may comprises cellulose derivatives without protolysable groups, for example ethyl cellulose.
- the metoprolol, or pharmaceutically acceptable salt thereof is preferably provided in the form of a granulated active ingredient. It may be present in an amount of from 12.5mg to 200mg in the composition, for example in an amount of 12.5mg, 25mg, 50mg, lOOmg or 200mg in the composition.
- the pharmaceutical composition according to the invention may further comprise a binder, for example a povidone.
- the hardness of the tablet may vary from 35 Nortons to 160 Nortons for tablets of different strengths.
- One preferred pharmaceutical composition according to the invention comprises: metoprolol succinate 27 to 30% microcrystalline cellulose 17 to 30% carbomer 1 to 6% hydroxypropyl methyl cellulose 14 to 56%
- the weight ratio of metoprolol, or pharmaceutically active salt thereof, to carbomer is in the range of 10: 1 to 1 : 12.
- Also provided in accordance with the invention is a process for the production of a pharmaceutical composition according to the invention, comprising blending metoprolol, or a pharmaceutically acceptable salt thereof, with a matrix material, granulating the blended mixture and compressing to form a tablet, and spray coating the tablet with a polymeric coating.
- At least one carbomer is preferably introduced into the composition during the blending and granulation steps.
- the tablet is prepared by a wet granulation process, preferably a non-aqueous process, for example a process using a hydroalcoholic wetting material
- the invention provides a process for preparing a pharmaceutical composition
- a process for preparing a pharmaceutical composition comprising: a) introduction of metoprolol succinate, carbomer and hydroxy polymethyl cellulose by blending, milling and sieving prior to granulation b) introduction of a solution of polymer in non-aqueous / hydroalcoholic solvent during granulation of the blended material as in (a) c) spray coating of the compressed tablets as in (c), with a water-insoluble polymeric membrane containing derivatives of cellulose without protolyasable groups d) thereby incorporating the tablet and the coating into a matrix forming a swelling gel in contact with water.
- a process for producing pharmaceutically extended-release preparations of metoprolol succinate is provided.
- the object of this invention is to obtain a solid preparation with high bioavailability of the drug in combination with an extended absorption in the gastrointestinal tract thus achieving an even effect of up to 24 hours after one (or twice in case of a lower dosage such as 12.5mg) daily administration.
- the present invention further provides a process for producing oral solid extended release pharmaceutical formulations, which releases metoprolol succinate over a time period of up to 24 hours.
- the carbomer is included in an amount from about 4.54% to about 11.5%, by weight of the final product.
- the drug to carbomer ratio may be, from about 10:1 to about 1:12 for example.
- the drug to carbomer ratio is from about 10:1.25 to about 1:12 by weight of formulation.
- the preparation of the said tablet is by compression and mixing of polymers.
- the carbomers are used in both granulation as well as mixing stages.
- extended release it is meant for purposes of the present invention that the therapeutically active medicament is released from the formulation at an extended rate such that therapeutically beneficial blood levels (but below toxic levels) of the medicament are maintained over an extended period of time, e.g., providing a 24 hour dosage form.
- the term "environment" is meant for purposes of the present invention to encompass a mammalian body, an organ of such a body or area of such a body, for example, the gastro-intestinal area. Such an environment can be tested by means of in-vitro dissolution testing, as is standard practice for testing of therapeutically active substances prior to use in mammalian bodies.
- the preparation may be manufactured into a commercially acceptable form, e.g. a tablet that shows unexpectedly good bioavailability of both active compounds as well as a prolonged duration of action.
- the active ingredient, MCC, carbopol and HPMC were blended together, and then the blend milled through a screen with appropriately size mesh.
- the blended material was then granulated with a solution of polymer in non-aqueous/ hydroalcoholic solvent.
- the granules were then dried at a suitable temperature and screened through a mesh of appropriate size.
- the blend was lubricated with a soluble or insoluble lubricant.
- the tablets were then formed by compression.
- composition of the tablets containing lOOmg metoprolol succinate without carbomer had the following composition:
- the coating solution to be applied to the tablets had the following composition:
- Titanium dioxide 3.8 %
- Tablets containing 12.5mg, 25 mg, 50 mg, and 200 mg were similarly prepared.
- a retarding coating solution with the following composition was used to further coat the tablets from Examples 1 and 3.
- Opadry OY-C-7000A (M/S coloreon) 4.5 % Ethyl cellulose 1.0 % Iso propyl alcohol qs Methylene chloride qs
- Dissolution tests were then carried out for the tablets produced in Examples 1-4.
- the dissolution tests were conducted in an automated USP dissolution apparatus (Paddle type II, pH 6.8 buffer, 50 rpm). The results are given in Table 5 & 6.
- Beta-blockers in chronic heart failure considerations for selecting an agent. Mayo Clin Proc 2002 Nov;77(l 1):1199-206.
- Metoprolol CR XL in female patients with heart failure analysis of the experience in
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003282375A AU2003282375A1 (en) | 2003-02-05 | 2003-09-17 | Pharmaceutical compositions and process of production thereof |
EP03773988A EP1589957A1 (de) | 2003-02-05 | 2003-09-17 | Pharmazeutische zusammensetzungen und herstellungsverfahren dafür |
NO20042890A NO20042890L (no) | 2003-02-05 | 2004-07-07 | Farmasoytiske preparater og fremgangsmate for fremstilling derav |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN151MU2003 | 2003-02-05 | ||
IN151/MUM/2003 | 2003-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004069234A1 true WO2004069234A1 (en) | 2004-08-19 |
Family
ID=32843822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2003/000312 WO2004069234A1 (en) | 2003-02-05 | 2003-09-17 | Pharmaceutical compositions and process of production thereof |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1589957A1 (de) |
AU (1) | AU2003282375A1 (de) |
NO (1) | NO20042890L (de) |
WO (1) | WO2004069234A1 (de) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007048233A1 (en) * | 2005-10-24 | 2007-05-03 | Orbus Pharma Inc. | Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist |
WO2007142546A2 (en) * | 2006-06-02 | 2007-12-13 | Zaklady Farmaceutyczne Polpharma S.A. | Sustained release coated tablet with precisely regulated release profile |
EP2255791A1 (de) * | 2009-04-03 | 2010-12-01 | Farmaprojects, S.A. | Pharmazeutische Zusammensetzung mit verlängerter Freisetzung mit Metoprololsuccinat |
CN102085195A (zh) * | 2011-01-10 | 2011-06-08 | 中国药科大学 | 琥珀酸美托洛尔缓释片及其制备方法 |
EP2361616A1 (de) | 2009-12-25 | 2011-08-31 | Dexcel Pharma Technologies Ltd. | Zusammensetzungen mit verzögerter Freisetzung für hohe Löslichkeit, hochdurchlässige pharmazeutische Wirkstoffe |
CN102008456B (zh) * | 2009-09-04 | 2015-01-14 | 鲁南制药集团股份有限公司 | 含有美托洛尔琥珀酸盐的新型骨架缓释片 |
WO2016138908A1 (en) | 2015-03-03 | 2016-09-09 | Saniona A/S | Tesofensine, beta blocker combination formulation |
WO2018204317A1 (en) * | 2017-05-02 | 2018-11-08 | Lubrizol Advanced Materials, Inc. | Improved extended release highly loaded drug compositions |
WO2020144146A1 (en) | 2019-01-07 | 2020-07-16 | Saniona A/S | Tesofensine for reduction of body weight in prader-willi patients |
WO2021214233A1 (en) | 2020-04-22 | 2021-10-28 | Saniona A/S | Treatment of hypothalamic obesity |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0148811A1 (de) * | 1984-01-10 | 1985-07-17 | Lejus Medical Aktiebolag | Pharmazeutische Komposition |
EP0210540A1 (de) * | 1985-07-19 | 1987-02-04 | Fujisawa Pharmaceutical Co., Ltd. | Zeitgesteuerte explodierende Systeme, sowie Verfahren zu deren Herstellung |
EP0237345A2 (de) * | 1986-03-12 | 1987-09-16 | Washington University Technology Associates, Inc. | Verfahren und Vorrichtung zum Granulieren und granuliertes Produkt |
WO2002058677A1 (en) * | 2001-01-24 | 2002-08-01 | Astrazeneca Ab | New film coating |
-
2003
- 2003-09-17 AU AU2003282375A patent/AU2003282375A1/en not_active Abandoned
- 2003-09-17 WO PCT/IN2003/000312 patent/WO2004069234A1/en not_active Application Discontinuation
- 2003-09-17 EP EP03773988A patent/EP1589957A1/de not_active Withdrawn
-
2004
- 2004-07-07 NO NO20042890A patent/NO20042890L/no not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0148811A1 (de) * | 1984-01-10 | 1985-07-17 | Lejus Medical Aktiebolag | Pharmazeutische Komposition |
EP0293347A1 (de) * | 1984-01-10 | 1988-11-30 | Aktiebolaget Hässle | Metoprololsuccinat und dieses enthaltende pharmazeutische Zusammensetzung |
EP0210540A1 (de) * | 1985-07-19 | 1987-02-04 | Fujisawa Pharmaceutical Co., Ltd. | Zeitgesteuerte explodierende Systeme, sowie Verfahren zu deren Herstellung |
EP0237345A2 (de) * | 1986-03-12 | 1987-09-16 | Washington University Technology Associates, Inc. | Verfahren und Vorrichtung zum Granulieren und granuliertes Produkt |
WO2002058677A1 (en) * | 2001-01-24 | 2002-08-01 | Astrazeneca Ab | New film coating |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007048233A1 (en) * | 2005-10-24 | 2007-05-03 | Orbus Pharma Inc. | Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist |
WO2007142546A2 (en) * | 2006-06-02 | 2007-12-13 | Zaklady Farmaceutyczne Polpharma S.A. | Sustained release coated tablet with precisely regulated release profile |
WO2007142546A3 (en) * | 2006-06-02 | 2008-02-21 | Zaklady Farm Polpharma Sa | Sustained release coated tablet with precisely regulated release profile |
EP2255791A1 (de) * | 2009-04-03 | 2010-12-01 | Farmaprojects, S.A. | Pharmazeutische Zusammensetzung mit verlängerter Freisetzung mit Metoprololsuccinat |
CN102008456B (zh) * | 2009-09-04 | 2015-01-14 | 鲁南制药集团股份有限公司 | 含有美托洛尔琥珀酸盐的新型骨架缓释片 |
EP2361616A1 (de) | 2009-12-25 | 2011-08-31 | Dexcel Pharma Technologies Ltd. | Zusammensetzungen mit verzögerter Freisetzung für hohe Löslichkeit, hochdurchlässige pharmazeutische Wirkstoffe |
CN102085195A (zh) * | 2011-01-10 | 2011-06-08 | 中国药科大学 | 琥珀酸美托洛尔缓释片及其制备方法 |
US9579288B2 (en) | 2015-03-03 | 2017-02-28 | Saniona A/S | Tesofensine and beta blocker combination formulations |
WO2016138908A1 (en) | 2015-03-03 | 2016-09-09 | Saniona A/S | Tesofensine, beta blocker combination formulation |
US10231951B2 (en) | 2015-03-03 | 2019-03-19 | Saniona A/S | Tesofensine, beta blocker combination formulation |
US10537551B2 (en) | 2015-03-03 | 2020-01-21 | Saniona A/S | Tesofensine and beta blocker combination formulations |
US10828278B2 (en) | 2015-03-03 | 2020-11-10 | Saniona A/S | Tesofensine and beta blocker combination formulations |
US11426383B2 (en) | 2015-03-03 | 2022-08-30 | Saniona A/S | Tesofensine and beta blocker combination formulations |
US12016840B2 (en) | 2015-03-03 | 2024-06-25 | Saniona A/S | Tesofensine and beta blocker combination formulations |
WO2018204317A1 (en) * | 2017-05-02 | 2018-11-08 | Lubrizol Advanced Materials, Inc. | Improved extended release highly loaded drug compositions |
CN110709068A (zh) * | 2017-05-02 | 2020-01-17 | 路博润先进材料公司 | 改进的缓释高负荷药物组合物 |
CN110709068B (zh) * | 2017-05-02 | 2022-11-08 | 路博润先进材料公司 | 改进的缓释高负荷药物组合物 |
WO2020144146A1 (en) | 2019-01-07 | 2020-07-16 | Saniona A/S | Tesofensine for reduction of body weight in prader-willi patients |
WO2021214233A1 (en) | 2020-04-22 | 2021-10-28 | Saniona A/S | Treatment of hypothalamic obesity |
Also Published As
Publication number | Publication date |
---|---|
EP1589957A1 (de) | 2005-11-02 |
NO20042890L (no) | 2004-07-07 |
AU2003282375A1 (en) | 2004-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6515010B1 (en) | Carvedilol methanesulfonate | |
JP3250737B2 (ja) | 放出制御製剤(アルブテロール) | |
US7374781B2 (en) | Sustained release formulations containing acetaminophen and tramadol | |
JP3893058B2 (ja) | 高度に可溶性の薬物のための徐放性マトリックス系 | |
US20060193911A1 (en) | Controlled release venlafaxine formulations | |
US20170007543A1 (en) | Sustained release of guaifenesin | |
NO340960B1 (no) | Modifiserte frigivende tamsulosintabletter | |
US20020182256A1 (en) | Novel oral dosage form for carvedilol | |
US20030224045A1 (en) | Combination immediate release sustained release levodopa/carbidopa dosage forms | |
WO2010128525A2 (en) | A formulation of ivabradine for treating the cardiovascular disease | |
CA2481739C (en) | Sustained release of guaifenesin combination drugs | |
US20030099710A1 (en) | Granule modulating hydrogel system | |
ZA200603421B (en) | A controlled release pharmaceutical composition and a process for preparing the same | |
EP1589957A1 (de) | Pharmazeutische zusammensetzungen und herstellungsverfahren dafür | |
US7985420B2 (en) | Sustained release of guaifenesin combination drugs | |
WO2006123213A1 (en) | Modified release formulations of gliclazide | |
WO2004078111A2 (en) | Extended release minocycline compositions and processes for their preparation | |
WO2007080776A1 (ja) | 徐放性製剤およびその製造方法 | |
AU2004299077A1 (en) | Sustained release torsemide dosage forms | |
EP2010158B1 (de) | Formulierungen mit kontrollierter freisetzung aus unbeschichteten diskreten einheiten und matrix mit verzögerter freisetzung | |
WO2006031024A1 (en) | A sustained-release tablet containing doxazosin mesylate | |
US20040228918A1 (en) | Granule modulating hydrogel system | |
WO2008038106A1 (en) | Venlafaxine extended release formulations | |
CN108721241A (zh) | 一种包含缬沙坦和氨氯地平的固体组合物及其制备方法 | |
NZ562286A (en) | Bi-layered modified release tablets for sustained release of guaifenesin combination drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2003773988 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 2003773988 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003773988 Country of ref document: EP |